No Data
Analysts Offer Insights on Healthcare Companies: Tarsus Pharmaceuticals (TARS), Climb Bio (CLYM) and Boston Scientific (BSX)
B. Riley Securities Initiates Climb Bio(CLYM.US) With Buy Rating, Announces Target Price $26
B. Riley Securities Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $26
This Evommune Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Truist Financial Maintains Climb Bio(CLYM.US) With Buy Rating, Maintains Target Price $17
Express News | Truist Securities Initiates Coverage On Climb Bio With Buy Rating, Announces Price Target of $17
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
